« Back to Farmacia Journal 1/2022
THE DIRECT COSTS BURDEN OF BEVACIZUMAB IN SOUTH-WEST ROMANIA
VALENTINA GHIMPĂU 1#, DANIEL SUR 2#, SIMONA RUXANDRA VOLOVĂȚ 3, IRINA MIHAELA CAZACU 4, VLAD MIHAI CROITORU 4, ADINA TURCU-ȘTIOLICĂ 5*, DAN IONUȚ GHEONEA 6, ADRIANA-ELENA TĂEREL 7#, MIHAELA-SIMONA SUBȚIRELU 5, CRISTIAN VIRGIL LUNGULESCU 8
1Doctoral School, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania
2Department of Medical Oncology, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400015, Cluj-Napoca, Romania
3Department of Oncology, “Grigore T Popa” University of Medicine and Pharmacy, 700115, Iași, Romania
4Department of Medical Oncology, “Fundeni” Clinical Institute, 022328, Bucharest, Romania
5Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania
6Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania 7Department of Pharmaceutical Management and Marketing, University of Medicine and Pharmacy “Carol Davila”, 020956,
Bucharest, Romania
8Department of Oncology, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania